60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $4.23 per share versus the Zacks Consensus Estimate of a loss of $3.96. This compares to loss of $16.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.82%. A quarter ago, it was expected that this company would post a loss of $1.92 per share when it actually produced earnings of $0.36, delivering a surprise of 118.75%. Over the last four quarters, th ...

Q2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ($124 thousand) to $35 thousand, year-over-year WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the second quarter of 2024, ended June 30, 2024. F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | --- | --- | ...

60 Degrees Pharmaceuticals (NASDAQ:SXTP) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky. This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria. This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied t ...

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of reference allows FDA to review 60 Degrees Pharma's regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company" or "60 Degrees Pharma" ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis ...

WASHINGTON, July 25, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it has been awarded a fixed-price contract with the United States Army Medical Materiel Development Activity to support commercial validation of new bottle and replacement blister packaging of ARAKODA® (tafenoquine), the Company's malaria prevention product. Tafenoquine was discovered b ...

WASHINGTON, July 25, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it has been awarded a fixed-price contract with the United States Army Medical Materiel Development Activity to support commercial validation of new bottle and replacement blister packaging of ARAKODA® (tafenoquine), the Company's malaria prevention product. expressed or implied in such ...

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tickborne, potentially life-threatening illness Case studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunos ...